GRTH and PRTH patients have resistance in the liver as documented by the measurement of sex-hormone-binding globulin, a peripheral marker of thyroid hormone action, whose levels are in the normal range, thus failing to distinguish between the two forms. 17, 18 The variability of the phenotype of subjects with RTH, including cardiac manifestations, derives from the different expression of TR isoforms in target tissue, which determines the different responsiveness to TH. 12 TRβ is expressed mainly in the hypothalamus, kidney, liver, anterior pituitary gland, hypothalamus, retina and cochlea, whereas
TRa predominates in the skeletal and cardiac muscle, brain, heart, brown fat, intestine, spleen and vascular endothelial cells.
Animal Model of Resistance to Thyroid Hormone
Data from knock-out (KO) mice suggest that TH achieve their action on the heart predominantly via TRa1. 4, [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] In TRa1 -/-mice, reduced heart rate (HR) and prolonged QRS-and QT-end-durations have been described. After T 3 administration, HR increases in TRa1 -/-mice, but to a much lesser degree compared with wt mice, even after prolonged exposure to high doses. 22 Conversely, TRβ -/-mice display a reduced QT end time 23 and an increased heart rate. Compared with wt mice, TRβ -/-showed similar decreases and increases in HR in response to TH deprivation and L-T 3 treatment, respectively. 24 Deletion of both TRa1 and TRβ results in a similar phenotype to TRa1 -/-mice, suggesting a crucial role of TRa1 in specific heart functions, namely regulation of pacemaker function and ventricular repolarisation. 22, 23 Transgenic KO of both TRa1 and TRa2 causes bradycardia and decreased myocardial contractility. 25 In these particular transgenic mice, HR increases with the administration of L-T 3 . This observation suggests that in the absence of TRa the heart rate is in the hypothyroid range, but can still be increased by TH, probably acting through the TRβ. 25 A reduction of HCN2 and HCN4 expression (genes coding for the cardiac pacemaker current) 26, 27 has been described. Moreover, these mice exhibit a reduced cardiac sensitivity to dynamic testing, supporting the hypothesis that TRa is the major functional cardiac TR isoform. 21, 25 The increased levels of HCN2 and HCN4 in TRβ -/-mice may be linked to TRa-mediated T 3 responsiveness, in fact reducing the high levels of TH in TRβ -/-; heart rate and HCN gene expression tend to normalise. 27 Mice 'knock-in' models [28] [29] [30] [31] [32] [33] [34] [35] have been generated in order to better understand the cardiac phenotype of RTH subjects. The PV mutation consists of a C-insertion at codon 448 in exon 10, which produces a frameshift of the carboxyl-terminal 14 amino acids of TRβ1 resulting in a complete loss of TH-binding activity. 31 The TRa PV/+ and TRβ PV/PV mutations lead, respectively, to opposite effects on energy metabolism in the heart: 28 cardiac glucose utilisation was reduced in the TRa PV/+ mutants and markedly enhanced in TRβ PV/PV . Moreover, TRa PV/+ show a reduction in heart size and blood pressure compared with wt mice, while heart size and blood pressure were normal in TRβ PV/PV mice. These data appear to be consistent with the alterations in cardiac function, such as bradycardia and reduced cardiac output, found in hypothyroidism and tachycardia associated with hyperthyroidism and RTH.
Svanson and collaborators 32 reported a decreased heart rate and a diminished contractile function in TRβ PV/PV mice when thyroid hormone levels were lowered into the normal range, suggesting that the homozygous PV mutant can negatively interfere with TRa1 signalling in the heart. These effects on the heart rate may be explained in part by a decreased expression of the ion channels. By contrast, the absence of functional consequences in TRβ PV/PV mutant mice with elevated thyroid hormone levels is likely due to an increased occupancy of TRa1. The expression of a mutant TRβ (Δ337T) in heart mice, driven by a β-actin promoter 33 or an MHCa promoter, 34 induces a hypothyroid phenotype in the heart, despite normal T 3 , thyroxine (T 4 ) and TSH levels in these mice. In isolated hearts particularly, the impairment of thyroid hormone action leads to left ventricular dysfunction; indeed, the cardiac performance measured in vivo is similar between wt and mutant animals, suggesting that other mechanisms could compensate in vivo the abnormalities of the mutant transgenic heart. 34 These findings are consistent with a dominant negative interference of wt TR function by the mutant TR and provide insight into the observation of the relative impairment in cardiac contractility seen in many patients with RTH. 39, 40 Indeed, the effects of RTH on the heart are complex and not completely explained by the heightened T 3 /TRa1 signalling, as suggested by the discordant cardiac gene expression profile between WT mice treated with T 3 and TRβ PV/PV . 35 Recently, it has been suggested that while TRa may be crucial for contractility, the β isoform could be involved in the regulation of cardiac energy substrate metabolism. 36 TRa -/-mice display a glucose/fatty acid oxidation balance comparable to wt. By contrast, TRβ KO exhibits a shift of metabolism towards glucose oxidation at the expense of fatty-
Thyroid Disorders 35 discovered increased systolic cardiac performance in adults affected with RTH. This finding suggests that the heart is relatively less resistant than other organs. Thus, the increase of contractility was less than expected given the level of thyroid hormone, implying the presence of some degree of resistance in the ventricle.
Moreover, given the fact that the increase of systolic cardiac performance was detected in adults only, the authors hypothesised that children with RTH could be more 'resistant' to thyroid hormone. A decrease in the mutant/normal receptor ratio with age was assumed as an explanation of these results. In contrast to previous reports, in the National Institutes of Health (NIH) study the resting pulse was found to be faster in RTH patients as a group, but not after adjustment for age.
Compared with normal controls, a higher frequency of valvular defects was observed, namely mitral valve prolapse in RTH subjects. More recently, Kahaly and collaborators 12 compared 54 RTH patients divided into three groups: healthy, hypothyroid and hyperthyroid patients. In agreement with previous data, they observed that in RTH some parameters (cardiac output, stroke volume and isovolumic relaxation and deceleration times) were moving towards hyperthyroidism, but others were not. Overall differences in terms of cardiovascular changes were smaller between the RTH and control group than between the RTH and the hyperthyroid or hypothyroid patients, suggesting an incomplete response of the heart to TH. Cardiovascular symptoms and signs were less frequent and severe in RTH compared with hyperthyroid subjects.
RTH subjects showed a systolic cardiac performance within the normal range; in particular, Doppler velocities, heart rate, stroke volume and cardiac output were significantly lower with respect to hyperthyroid subjects. In comparison with controls, RTH patients exhibit an enhanced left ventricular (LV) contractile function and shorter diastolic parameters, while systolic and diastolic diameters of the LV were not significantly different. Interestingly, in RTH subjects without cardiac signs, median age, heart rate and TH levels were higher and diastolic relaxation time was shorter compared with those with palpitations and tachycardia. Nevertheless, all other cardiovascular parameters showed no significant differences. Even if the heart rate was high, especially in subjects harbouring the mutations Y321S, M334R and C446R, no significant correlation was found between cardiovascular features and the type of mutation.
To a certain extent, some of these results were in contrast to the previous NIH paper. 39 Notably, in the Kahaly et al. paper a higher heart rate in RTH was discovered. Moreover, the frequency of mitral valve prolapse was not increased in RTH compared with controls.
Remarkably, a significantly higher heart rate and a larger diameter of the left atrium (LA) and lower LV ejection fraction were found in affected children compared with controls of comparable age, while in the Brucker-Davis paper adults but not children exhibited improved of systolic cardiac performance. We have recently published data that are apparently different from those of Kahaly and collaborators, model of RTH displays an impaired endothelial vascular function and hypercholesterolaemia compared with wt controls. 43 In the vascular endothelial cell the predominant TR isoform is TRa. Equally, these data suggest that TRβ may have a certain role in endothelial function.
However, a number of the rapid effects of thyroid hormone on the vascular wall are mediated via a non-genomic mechanism.
Furthermore, the elevated arterial stiffness may lead to increased cardiovascular risk in RTH.
Ciulla and co-workers 44 found that the echoreflectivity (dCVF%) of interventricular septum was slightly higher in the RTH patients compared with controls and hyperthyroid subjects, but lower than in hypothyroid patients. The echoreflectivity is a marker of fibrous myocardial remodelling related to increased myocardial collagen deposition. This parameter represents a risk factor for the performance of coronary circulation, systodiastolic function and electric stability of the heart. As suggested by animal models of hypothyroidism, 45, 46 cholesterol levels in RTH subjects compared with controls. 42 Furthermore, dyslipidaemia is associated with reduced nitric oxide bioavailability and impairment of smooth-muscle relaxation that could also increase arterial stiffness.
Mitchell and co-workers (personal communication) observed that the insulin sensitivity index (ISI) and homeostasis model assessmentinsulin resistance (HOMA-IR) was strikingly elevated in a group of RTH subjects compared with controls. Moreover, plasma free fatty acid (FFA) concentrations were ~30%, high-density lipoprotein (HDL) cholesterol was significantly reduced and triglycerides were slightly elevated. This finding could be consistent with increased sympathetic activity and adipose tissue lipolisys. Remarkably, the strong correlation between fasting plasma FFA concentrations and insulin resistance is well-known. The mechanism for this is unclear: one hypothesis is that skeletal muscle metabolism of fatty acid is impaired, leading to muscle lipotoxicity and impaired insulin action;
alternatively, RTH subjects exhibit hepatic RTH action that may also be associated with reduced hepatic sensitivity to insulin action.
Conclusion
In addition to reduced vascular compliance and echocardiographic abnormalities, RTH subjects exhibit some features of metabolic syndrome, such as insulin resistance together with elevated circulating triglycerides and reduced HDL cholesterol levels, which suggests that overall cardio-metabolic risk in this disorder may be increased. n His major research interest is the pathophysiology of the hypothalamic-pituitary-thyroid axis.
